NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
12.34 ^USD	+2.36%		+2.41%	-17.35%

Apr. 24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
Apr. 10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

February 24, 2022 at 07:01 am EST

NovoCure Limited reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported sales was USD 133.21 million compared to USD 143.95 million a year ago. Net loss was USD 26.46 million compared to net income of USD 4.92 million a year ago.

Basic loss per share from continuing operations was USD 0.25 compared to basic earnings per share from continuing operations of USD 0.05 a year ago. Diluted loss per share from continuing operations was USD 0.25 compared to diluted earnings per share from continuing operations of USD 0.04 a year ago.

Latest news about NovoCure Limited

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	Apr. 24	CI
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	Apr. 10	MT
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	Apr. 05	MT
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	Apr. 03	MT
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients	Mar. 27	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
Sector Update: Health Care	Mar. 27	MT
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell	Mar. 27	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	Mar. 27	MT
Transcript : NovoCure Limited - Special Call	Mar. 27
Novocure's lung cancer therapy succeeds in late-stage trial	Mar. 27	RE
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	Feb. 23	MT
Novocure Q4 Net Loss Widens, Revenue Rises	Feb. 22	MT
Transcript : NovoCure Limited, Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $133.8M	Feb. 22	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	Jan. 18	MT
Top Midday Gainers	Jan. 18	MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon	Jan. 18	MT
NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise	Jan. 18	MT
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application	Jan. 18	DJ
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	Jan. 18	CI
Transcript : NovoCure Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	Jan. 10
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma	Jan. 09	CI

Chart NovoCure Limited

Duration

Period

More charts

Company Profile

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for NovoCure Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.34 USD

Average target price

26.17 USD

Spread / Average Target

+112.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
NOVOCURE LIMITED	-17.35%	1.33B
SHOCKWAVE MEDICAL, INC.	+72.58%	12.34B
PENUMBRA, INC.	-18.04%	7.98B
GETINGE AB	+3.57%	5.81B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.65%	5.04B
APT MEDICAL INC.	+20.83%	4.31B
ASAHI INTECC CO., LTD.	-20.34%	4.03B
INARI MEDICAL, INC.	-41.19%	2.21B
SKAN GROUP AG	+0.25%	1.99B
SHENZHEN YHLO BIOTECH CO., LTD.	+4.02%	1.87B

Medical Equipment